Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells.

Laursen EB, Fredsøe J, Schmidt L, Strand S, Kristensen H, Ildor Rasmussen AK, Daugaard TF, Mouritzen P, Høyer S, Kristensen G, Stroomberg HV, Brasso K, Røder MA, Borre M, Sørensen KD.

Am J Pathol. 2019 Sep 17. pii: S0002-9440(19)30711-4. doi: 10.1016/j.ajpath.2019.08.007. [Epub ahead of print]

2.

Risk of Depression After Radical Prostatectomy-A Nationwide Registry-based Study.

Friberg AS, Dalton SO, Larsen SB, Andersen EW, Krøyer A, Helgstrand JT, Røder MA, Johansen C, Brasso K.

Eur Urol Oncol. 2019 Jul 22. pii: S2588-9311(19)30101-4. doi: 10.1016/j.euo.2019.06.020. [Epub ahead of print]

PMID:
31345731
3.

Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis.

Kristensen G, Berg KD, Toft BG, Stroomberg HV, Nolley R, Brooks JD, Brasso K, Roder MA.

J Clin Pathol. 2019 Oct;72(10):696-704. doi: 10.1136/jclinpath-2019-205940. Epub 2019 Jul 22.

PMID:
31331953
4.

Prognostic implication of gait function following treatment for spinal cord compression in men diagnosed with prostate cancer.

Lehrmann-Lerche CS, Thomsen FB, Røder MA, Suppli MH, Brasso K, Berg KD.

Scand J Urol. 2019 Jun 17:1-7. doi: 10.1080/21681805.2019.1626478. [Epub ahead of print]

PMID:
31204549
5.

Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer.

Thomsen FB, Røder MA, Jakobsen H, Langkilde NC, Borre M, Jakobsen EB, Frey A, Lund L, Lunden D, Dahl C, Brasso K.

Clin Genitourin Cancer. 2019 Aug;17(4):e814-e821. doi: 10.1016/j.clgc.2019.05.005. Epub 2019 May 21.

PMID:
31196798
6.

Palliative Prostate Artery Embolization for Prostate Cancer: A Case Series.

Malling B, Røder MA, Lindh M, Frevert S, Brasso K, Lönn L.

Cardiovasc Intervent Radiol. 2019 Oct;42(10):1405-1412. doi: 10.1007/s00270-019-02227-4. Epub 2019 May 6.

PMID:
31062066
7.

Prostate Artery Embolization for Lower Urinary Tract Symptoms in Men Unfit for Surgery.

Malling B, Lönn L, Jensen RJ, Lindh M, Frevert S, Brasso K, Røder MA.

Diagnostics (Basel). 2019 Apr 25;9(2). pii: E46. doi: 10.3390/diagnostics9020046.

8.

5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors.

Kristensen G, Strand SH, Røder MA, Berg KD, Toft BG, Høyer S, Borre M, Sørensen KD, Brasso K.

Int J Mol Sci. 2019 Feb 27;20(5). pii: E1025. doi: 10.3390/ijms20051025.

9.

The prognostic impact of incidental prostate cancer following radical cystoprostatectomy: a nationwide analysis.

Jønck S, Helgstrand JT, Røder MA, Klemann N, Grønkaer Toft B, Brasso K.

Scand J Urol. 2018 Oct - Dec;52(5-6):358-363. doi: 10.1080/21681805.2018.1534885. Epub 2019 Jan 9.

PMID:
30624125
10.

Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Olama AAA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA; Profile Study; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium.

Nat Genet. 2019 Feb;51(2):363. doi: 10.1038/s41588-018-0330-6.

PMID:
30622367
11.

[Prostate cancer surgery].

Røder MA, Iversen P.

Ugeskr Laeger. 2018 Nov 12;180(46). pii: V02180095. Danish.

PMID:
30417813
12.

Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.

Flores-Morales A, Bergmann TB, Lavallee C, Batth TS, Lin D, Lerdrup M, Friis S, Bartels A, Kristensen G, Krzyzanowska A, Xue H, Fazli L, Hansen KH, Røder MA, Brasso K, Moreira JM, Bjartell A, Wang Y, Olsen JV, Collins CC, Iglesias-Gato D.

Clin Cancer Res. 2019 Jan 15;25(2):595-608. doi: 10.1158/1078-0432.CCR-18-0729. Epub 2018 Oct 1.

PMID:
30274982
13.

Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer.

Kristensen G, Røder MA, Berg KD, Elversang J, Iglesias-Gato D, Moreira J, Toft BG, Brasso K.

APMIS. 2018 Oct;126(10):804-813. doi: 10.1111/apm.12886. Epub 2018 Sep 6.

PMID:
30191621
14.

[Prostate artery embolisation is a new treatment for prostate disease].

Malling B, Lönn LB, Frevert S, Lindh M, Bagi P, Vejborg I, Brasso K, Røder MA.

Ugeskr Laeger. 2018 Aug 13;180(33). pii: V01180004. Danish.

PMID:
30084348
15.

Prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-analysis.

Malling B, Røder MA, Brasso K, Forman J, Taudorf M, Lönn L.

Eur Radiol. 2019 Jan;29(1):287-298. doi: 10.1007/s00330-018-5564-2. Epub 2018 Jun 14.

PMID:
29948079
16.

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z.

Nat Commun. 2018 Jun 11;9(1):2256. doi: 10.1038/s41467-018-04109-8.

17.

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA; Profile Study; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium.

Nat Genet. 2018 Jul;50(7):928-936. doi: 10.1038/s41588-018-0142-8. Epub 2018 Jun 11. Erratum in: Nat Genet. 2019 Feb;51(2):363.

18.

Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.

Helgstrand JT, Røder MA, Klemann N, Toft BG, Lichtensztajn DY, Brooks JD, Brasso K, Vainer B, Iversen P.

Cancer. 2018 Jul 15;124(14):2931-2938. doi: 10.1002/cncr.31384. Epub 2018 May 3.

19.

The use of transrectal ultrasound-guided biopsy following the introduction of prostate-specific antigen testing in Denmark: a population-based analysis.

Klemann N, Røder MA, Helgstrand JT, Brasso K, Toft BG, Vainer B, Iversen P.

Scand J Urol. 2018 Jun;52(3):169-173. doi: 10.1080/21681805.2018.1444672. Epub 2018 Mar 8.

PMID:
29514539
20.

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.

Seibert TM, Fan CC, Wang Y, Zuber V, Karunamuni R, Parsons JK, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Garcia SB, Muir K, Grönberg H, Wiklund F, Aly M, Schleutker J, Sipeky C, Tammela TL, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokolorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Cuk K, Saum KU, Park JY, Sellers TA, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Karow DS, Mills IG, Andreassen OA, Dale AM; PRACTICAL Consortium*.

BMJ. 2018 Jan 10;360:j5757. doi: 10.1136/bmj.j5757.

21.

Temporal Trends in Clinical and Pathological Characteristics for Men Undergoing Radical Prostatectomy Between 1995 and 2013 at Rigshospitalet, Copenhagen, Denmark, and Stanford University Hospital, United States.

Loft MD, Berg KD, Kjaer A, Iversen P, Ferrari M, Zhang CA, Brasso K, Brooks JD, Røder MA.

Clin Genitourin Cancer. 2017 Sep 6. pii: S1558-7673(17)30269-0. doi: 10.1016/j.clgc.2017.08.014. [Epub ahead of print]

PMID:
28988695
22.

Cytoreductive prostatectomy in metastatic prostate cancer: a systematic review.

Becker JA, Berg KD, Røder MA, Brasso K, Iversen P.

Scand J Urol. 2018 Feb;52(1):1-7. doi: 10.1080/21681805.2017.1363816. Epub 2017 Aug 18. Review.

PMID:
28818014
23.

Diagnostic characteristics of lethal prostate cancer.

Helgstrand JT, Røder MA, Klemann N, Toft BG, Brasso K, Vainer B, Iversen P.

Eur J Cancer. 2017 Oct;84:18-26. doi: 10.1016/j.ejca.2017.07.007. Epub 2017 Aug 2.

PMID:
28779631
24.

The risk of biochemical recurrence for intermediate-risk prostate cancer after radical prostatectomy.

Kurbegovic S, Berg KD, Thomsen FB, Gruschy L, Iversen P, Brasso K, Røder MA.

Scand J Urol. 2017 Dec;51(6):450-456. doi: 10.1080/21681805.2017.1356369. Epub 2017 Aug 1.

PMID:
28762283
25.

Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study.

Steuber T, Berg KD, Røder MA, Brasso K, Iversen P, Huland H, Tiebel A, Schlomm T, Haese A, Salomon G, Budäus L, Tilki D, Heinzer H, Graefen M, Mandel P.

Eur Urol Focus. 2017 Dec;3(6):646-649. doi: 10.1016/j.euf.2017.06.016. Epub 2017 Jul 8.

PMID:
28753877
26.

The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy.

Røder MA, Berg KD, Loft MD, Thomsen FB, Ferrari M, Kurbegovic S, Rytgaard HC, Gruschy L, Brasso K, Gerds TA, Kjær A, Brooks JD, Iversen P.

Eur Urol Focus. 2018 Apr;4(3):360-368. doi: 10.1016/j.euf.2016.11.014. Epub 2016 Dec 9.

PMID:
28753827
27.

Plasma levels of intact and cleaved urokinase plasminogen activator receptor (uPAR) in men with clinically localised prostate cancer.

Kristensen G, Berg KD, Lippert S, Christensen IJ, Brasso K, Høyer-Hansen G, Røder MA.

J Clin Pathol. 2017 Dec;70(12):1063-1068. doi: 10.1136/jclinpath-2017-204475. Epub 2017 Jun 12.

PMID:
28607123
28.

Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up.

Heering M, Berg KD, Brasso K, Iversen P, Røder MA.

Surg Oncol. 2017 Mar;26(1):21-27. doi: 10.1016/j.suronc.2016.12.002. Epub 2016 Dec 8.

PMID:
28317581
29.

The drama of prostate cancer diagnostics - Authors' reply.

Iversen P, Røder MA, Klemann N.

Lancet Oncol. 2017 Mar;18(3):e133. doi: 10.1016/S1470-2045(17)30120-1. Epub 2017 Mar 2. No abstract available.

PMID:
28271866
30.

Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study.

Klemann N, Røder MA, Helgstrand JT, Brasso K, Toft BG, Vainer B, Iversen P.

Lancet Oncol. 2017 Feb;18(2):221-229. doi: 10.1016/S1470-2045(17)30025-6. Epub 2017 Jan 14.

PMID:
28094199
31.

Antibiotic prophylaxis and complications following prostate biopsies - a systematic review.

Klemann N, Helgstrand JT, Brasso K, Vainer B, Iversen P, Røder MA.

Dan Med J. 2017 Jan;64(1). pii: A5323. Review.

PMID:
28007054
32.

Danish Prostate Cancer Registry - methodology and early results from a novel national database.

Helgstrand JT, Klemann N, Røder MA, Toft BG, Brasso K, Vainer B, Iversen P.

Clin Epidemiol. 2016 Sep 27;8:351-360. eCollection 2016.

33.

A single-center experience with abiraterone as treatment for metastatic castration-resistant prostate cancer.

Thortzen A, Thim S, Røder MA, Brasso K.

Urol Oncol. 2016 Jul;34(7):291.e1-7. doi: 10.1016/j.urolonc.2016.02.013. Epub 2016 Mar 9.

PMID:
26971191
34.

Anastomotic complications after robot-assisted laparoscopic and open radical prostatectomy.

Jacobsen A, Berg KD, Iversen P, Brasso K, Røder MA.

Scand J Urol. 2016 Aug;50(4):274-9. doi: 10.3109/21681805.2016.1145735. Epub 2016 Mar 10.

PMID:
26963663
35.

Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide.

Anand A, Morris MJ, Larson SM, Minarik D, Josefsson A, Helgstrand JT, Oturai PS, Edenbrandt L, Røder MA, Bjartell A.

EJNMMI Res. 2016 Dec;6(1):23. doi: 10.1186/s13550-016-0173-z. Epub 2016 Mar 9.

36.

Systematic review: does endocrine therapy prolong survival in patients with prostate cancer?

Helgstrand JT, Berg KD, Lippert S, Brasso K, Røder MA.

Scand J Urol. 2016 Jun;50(3):135-43. doi: 10.3109/21681805.2016.1142472. Epub 2016 Feb 23. Review.

PMID:
26907159
37.

The impact of the 2005 International Society of Urological Pathology consensus guidelines on Gleason grading - a matched-pair analysis.

Berg KD, Thomsen FB, Nerstrøm C, Røder MA, Iversen P, Toft BG, Vainer B, Brasso K.

BJU Int. 2016 Jun;117(6):883-9. doi: 10.1111/bju.13439. Epub 2016 Feb 22.

38.

Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results.

Lippert S, Berg KD, Høyer-Hansen G, Lund IK, Iversen P, Christensen IJ, Brasso K, Røder MA.

Biomark Med. 2016;10(2):209-16. doi: 10.2217/bmm.15.114. Epub 2016 Jan 14.

PMID:
26764285
39.

ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer.

Berg KD, Brasso K, Thomsen FB, Røder MA, Holten-Rossing H, Toft BG, Iversen P, Vainer B.

J Clin Pathol. 2015 Oct;68(10):788-94. doi: 10.1136/jclinpath-2015-202894. Epub 2015 Jun 9.

PMID:
26060265
40.

The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.

Berg KD, Røder MA, Thomsen FB, Vainer B, Gerds TA, Brasso K, Iversen P.

Prostate. 2015 Oct;75(14):1499-509. doi: 10.1002/pros.23026. Epub 2015 Jun 5.

PMID:
26053696
41.

[Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatment].

Djurhuus SS, Brasso K, Berg KD, Iversen P, Røder MA.

Ugeskr Laeger. 2015 May 11;177(20). pii: V11140628. Review. Danish.

PMID:
25967247
42.

Length of life gained with surgical treatment of prostate cancer: A population-based analysis.

Røder MA, Brasso K, Rusch E, Johansen J, Langkilde NC, Hvarness H, Carlsson S, Jakobsen H, Borre M, Iversen P.

Scand J Urol. 2015;49(4):275-81. doi: 10.3109/21681805.2014.984324. Epub 2014 Dec 2.

PMID:
25438988
43.

Active surveillance for localized prostate cancer: an analysis of patient contacts and utilization of healthcare resources.

Thomsen FB, Berg KD, Røder MA, Iversen P, Brasso K.

Scand J Urol. 2015 Feb;49(1):43-50. doi: 10.3109/21681805.2014.970572. Epub 2014 Nov 3.

PMID:
25363612
44.

A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.

Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, Benlloch S, Hazelett DJ, Wang Z, Saunders E, Leongamornlert D, Lindstrom S, Jugurnauth-Little S, Dadaev T, Tymrakiewicz M, Stram DO, Rand K, Wan P, Stram A, Sheng X, Pooler LC, Park K, Xia L, Tyrer J, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Yeager M, Burdette L, Chung CC, Hutchinson A, Yu K, Goh C, Ahmed M, Govindasami K, Guy M, Tammela TL, Auvinen A, Wahlfors T, Schleutker J, Visakorpi T, Leinonen KA, Xu J, Aly M, Donovan J, Travis RC, Key TJ, Siddiq A, Canzian F, Khaw KT, Takahashi A, Kubo M, Pharoah P, Pashayan N, Weischer M, Nordestgaard BG, Nielsen SF, Klarskov P, Røder MA, Iversen P, Thibodeau SN, McDonnell SK, Schaid DJ, Stanford JL, Kolb S, Holt S, Knudsen B, Coll AH, Gapstur SM, Diver WR, Stevens VL, Maier C, Luedeke M, Herkommer K, Rinckleb AE, Strom SS, Pettaway C, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, Cannon-Albright L, Cybulski C, Wokołorczyk D, Kluźniak W, Park J, Sellers T, Lin HY, Isaacs WB, Partin AW, Brenner H, Dieffenbach AK, Stegmaier C, Chen C, Giovannucci EL, Ma J, Stampfer M, Penney KL, Mucci L, John EM, Ingles SA, Kittles RA, Murphy AB, Pandha H, Michael A, Kierzek AM, Blot W, Signorello LB, Zheng W, Albanes D, Virtamo J, Weinstein S, Nemesure B, Carpten J, Leske C, Wu SY, Hennis A, Kibel AS, Rybicki BA, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Zheng SL, Batra J, Clements J, Spurdle A, Teixeira MR, Paulo P, Maia S, Slavov C, Kaneva R, Mitev V, Witte JS, Casey G, Gillanders EM, Seminara D, Riboli E, Hamdy FC, Coetzee GA, Li Q, Freedman ML, Hunter DJ, Muir K, Gronberg H, Neal DE, Southey M, Giles GG, Severi G; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; COGS (Collaborative Oncological Gene-environment Study) Consortium; GAME-ON/ELLIPSE Consortium, Cook MB, Nakagawa H, Wiklund F, Kraft P, Chanock SJ, Henderson BE, Easton DF, Eeles RA, Haiman CA.

Nat Genet. 2014 Oct;46(10):1103-9. doi: 10.1038/ng.3094. Epub 2014 Sep 14.

45.

ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer.

Berg KD, Vainer B, Thomsen FB, Røder MA, Gerds TA, Toft BG, Brasso K, Iversen P.

Eur Urol. 2014 Nov;66(5):851-60. doi: 10.1016/j.eururo.2014.02.058. Epub 2014 Mar 7.

PMID:
24630684
46.

Active surveillance for clinically localized prostate cancer--a systematic review.

Thomsen FB, Brasso K, Klotz LH, Røder MA, Berg KD, Iversen P.

J Surg Oncol. 2014 Jun;109(8):830-5. doi: 10.1002/jso.23584. Epub 2014 Mar 7. Review.

PMID:
24610744
47.

Non-apical positive surgical margins after radical prostatectomy for pT2 prostate cancer is associated with the highest risk of recurrence.

Røder MA, Kawa S, Scheike T, Toft BG, Hansen JB, Brasso K, Vainer B, Iversen P.

J Surg Oncol. 2014 Jun;109(8):818-22. doi: 10.1002/jso.23573. Epub 2014 Feb 13.

PMID:
24522971
49.

Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.

Thomsen FB, Røder MA, Rathenborg P, Brasso K, Borre M, Iversen P.

Scand J Urol. 2014 Jun;48(3):268-75. doi: 10.3109/21681805.2013.860189. Epub 2013 Nov 21.

PMID:
24255983
50.

Risk of biochemical recurrence and positive surgical margins in patients with pT2 prostate cancer undergoing radical prostatectomy.

Røder MA, Thomsen FB, Berg KD, Christensen IB, Brasso K, Vainer B, Iversen P.

J Surg Oncol. 2014 Feb;109(2):132-8. doi: 10.1002/jso.23469. Epub 2013 Oct 24.

PMID:
24155174

Supplemental Content

Loading ...
Support Center